"ESMO 2025: Padcev plus Keytruda promising in first-line advanced HNSCC" was originally created and published by Clinical ...
Merck (NYSE:MRK) announced on Thursday that the FDA has granted priority review for two of its marketing applications aimed ...
Moderna has shared some of the phase 1/2 data that persuaded it to expand and p | Moderna has shared some of the phase 1/2 ...
The FDA accepted an application for Padcev plus Keytruda for patients with muscle-invasive bladder cancer ineligible for ...
IO102-IO103 plus Keytruda improved median PFS by 8.4 months over Keytruda alone in advanced melanoma patients. The ...
Results from the pivotal EV-303 trial demonstrated that, when used before and after surgery, the combination reduced the risk of recurrence, progression or death by 60% and the risk of death by 50% in ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...
"ESMO 2025: J&J eyes Rybrevant indication expansion to HNSCC on Phase II victory" was originally created and published by ...
CAMBRIDGE, United Kingdom, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic ...
Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancers First-in-class multi-checkpoint inhibitor with robust ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback